NCT05563571 is a NA clinical trial of Methylprednisolon, Lidocaine in Stroke, sponsored by Satasairaala.

Who is sponsoring NCT05563571?

NCT05563571 is sponsored by Satasairaala.

What drugs are being tested in NCT05563571?

Interventions in NCT05563571: Methylprednisolon, Lidocaine, Pulsed radiofrequency, Lidocaine.

What condition does NCT05563571 study?

NCT05563571 studies Stroke, Shoulder Pain.

Is NCT05563571 still recruiting?

NCT05563571 is currently status unknown. Last updated 3 October 2022.

Last reviewed 2022-10-03 · How we verify

NCT05563571

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hemiplegic Shoulder Pain Management Using Shoulder pRF and Corticosteroid Injection

Status unknown NA Last updated 3 October 2022

What this trial tests

NA trial testing Methylprednisolon, Lidocaine in Stroke in 20 participants. Status unknown.

Timeline

1 April 2022

Primary endpoint
1 January 2024

1 April 2024

Quick facts

Lead sponsor	Satasairaala
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	20
Start date	1 April 2022
Primary completion	1 January 2024
Estimated completion	1 April 2024
Sites	1 location across Finland

Drugs / interventions tested

Methylprednisolon, Lidocaine — full drug profile →
Pulsed radiofrequency, Lidocaine

Conditions studied

Stroke — all drugs for Stroke →
Shoulder Pain — all drugs for Shoulder Pain →

Sponsor

Satasairaala — full company profile →

Who can join

Adults 18 to 80, any sex, with Stroke or Shoulder Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Introduction: hemiplegic shoulder pain (HSP) in a common post-stroke condition, that can lead to poor motor and functional recovery and lower quality of life. Interventions like intra-articular corticosteroid injection (ICI) and suprascapularis nerve (SSN) pulsed radiofrecuenfy treatment (PRF) has been used to treat the pain. Methods: in this single-center, prospective, randomized controlled study, we included 20 consecutive patients with hemiplegic shoulder pain in subacute stroke phase (2-12 months after diagnosis). Subjects were randomly assigned to the PRF (SSN and shoulder joint) and ICI treatment groups (n = 10 in each). Primary outcome is hemiplegic shoulder pain severity, measured by numeric rating scale, active shoulder range of motion and Fugl-Meyer upper limb assessment. Secondary outcome is shoulder joint and cervicocephalic kinesthetic sensibility. Outcome measurements were assessed at baseline and one, two and six months after each procedure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

NCT06615973 — Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke · recruiting
NCT07494890 — Measurement Properties of Mechanical Cost of Walking for Individuals With Walking Impairment · NA · recruiting
NCT07356011 — Exoskeleton for Balance · NA · recruiting
NCT07523503 — Unilateral Versus Bilateral Task-specific Training on Motor Impairment, Upper Extremity Function, and Hand Dexterity in · NA · recruiting
NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients · NA · recruiting

Other Satasairaala trials

Trials by the same sponsor.

NCT05520489 — Upper Limb Rehabilitation in First Year After Stroke Using Modern Treatment Strategies - a Single Case Study · NA · unknown
NCT04737993 — Pulsed Radiofrequency of Suprascapular Nerve and Shoulder Joint for Chronic Shoulder Pain · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05563571 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Satasairaala
Last refreshed: 3 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05563571.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing